1. This site uses cookies. By continuing to use this site, you are agreeing to our use of cookies. Learn More.
STOP -BY READING OR VISITING THESE FORUMS YOU MUST AGREE TO THE FOLLOWING:
By reading or entering these forums you contractually agree to the following:

•  You are 18 years of age or older and you are accessing this website for personal use only!
•  By viewing these forums, you certify you are not a member or affiliated with any of the following: Voices for Vaccines, CDC, Emory University, Task Force for Global Health, UC Hastings, FDA, World Health Organization, Bill and Melinda Gates Foundation or any other group pushing vaccination, or vaccination compliance.
•  You are not a member, employer, employee, sympathizer, freelancer, representative of any pharmaceutical company.
•  You are not a member of Antivax wall of shame, Embarrassed Cousins of Proud Parents of Unvaccinated Children or other similar organization/groups, or any that bullies, demeans, make fun of, or harasses those w/ different beliefs on vaccinations.
•  This is a contractual agreement, and you contractually agree not to screenshot, or share our material in groups such as Antivax Wall of Shame, or any similar groups or any previously mentioned groups.

If you do not agree to all of the above or if you do not meet all of the above conditions, you will leave these forums immediately.

Evolution of multiple sclerosis in France since the beginning of hepatitis B vaccination

Discussion in 'Studies' started by Veritas Dolor, May 30, 2019.

  1. Veritas Dolor

    Veritas Dolor vActivist Administrator

    Likes Received:
    85
    Trophy Points:
    28
    Home Page:
    This study on hep b and an increase in ms states the following as their conclusion:

    Conclusions
    The figures available in France thus show a definite statistical signal in favor of a causal link between the HB vaccine event and the apparition of MS with a maximum correlation in the 2 years following immunization. The impact of other factors (new use of MRI, beginning of interferon-beta) is probably associated. The weakness of this study is its retrospective nature and therefore subject to bias of notoriety. Its strength is that it is based on indisputable official data on large numbers and during about 12 years. The appearance of a spectacular “vaccine wave” in France has remained the only one in its kind. The intensive lobbying carried out in the years 1994–1997 led to concentrate as many vaccinated people as possible in the shortest period of time. This particularity is perhaps the explanation of the emergence of the problem of post-vaccine MS, especially recorded in this country. The low overall frequency of this adverse effect, not measurable in most epidemiological studies, here becomes more obvious because of a kind of involuntary very large scale experiment carried out on a third of the French population. All this is expected to require further epidemiological studies, particularly from the French health insurance data. Indeed, CNAM has information on millions of insured persons for many years that would be usable if we could more easily access it.

    Read the full study:
    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4266455/
     

Share This Page